Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Medicina (Kaunas) ; 58(5)2022 Apr 22.
Article in English | MEDLINE | ID: covidwho-1875695

ABSTRACT

Oral fungal infections are a worldwide healthcare problem. Although Candida albicans is still the most common yeast involved in the infections of oral cavity, non-Candida albicans Candida species (NCACs) have been highly related to these infections, particularly in older, immunosuppressed or patients with long exposure to antimicrobial drugs. The goal of this work was to perform a quick epidemiological and mycological study on the oral samples collected from a laboratory of a hospital in Slovakia, for 60 days. The samples' identification was performed by Germ-tube formation test, CHROMID® Candida, Auxacolor 2, ID 32C automated method, and the antifungal susceptibility testing determined by E-test®. Results confirm that comparing with bacteria, yeasts still occur in the lower number, but there is a high rate of antifungal resistance (81.6%)-to, at least one drug-among the collected samples, particularly to azoles and 5'-FC, which is clinically noteworthy.


Subject(s)
Antifungal Agents , Candida , Aged , Antifungal Agents/pharmacology , Antifungal Agents/therapeutic use , Fluconazole , Hospitals , Humans , Microbial Sensitivity Tests , Prevalence , Slovakia/epidemiology
2.
J Fungi (Basel) ; 7(9)2021 Sep 02.
Article in English | MEDLINE | ID: covidwho-1390674

ABSTRACT

Patients with severe COVID-19, such as individuals in intensive care units (ICU), are exceptionally susceptible to bacterial and fungal infections. The most prevalent fungal infections are aspergillosis and candidemia. Nonetheless, other fungal species (for instance, Histoplasma spp., Rhizopus spp., Mucor spp., Cryptococcus spp.) have recently been increasingly linked to opportunistic fungal diseases in COVID-19 patients. These fungal co-infections are described with rising incidence, severe illness, and death that is associated with host immune response. Awareness of the high risks of the occurrence of fungal co-infections is crucial to downgrade any arrear in diagnosis and treatment to support the prevention of severe illness and death directly related to these infections. This review analyses the fungal infections, treatments, outcome, and immune response, considering the possible role of the microbiome in these patients. The search was performed in Medline (PubMed), using the words "fungal infections COVID-19", between 2020-2021.

3.
Front Pharmacol ; 12: 575877, 2021.
Article in English | MEDLINE | ID: covidwho-1314562

ABSTRACT

The current coronavirus disease (COVID-19) outbreak is a significant threat to human health and the worldwide economy. Coronaviruses cause a variety of diseases, such as pneumonia-like upper respiratory tract illnesses, gastroenteritis, encephalitis, multiple organ failure involving lungs and kidneys which might cause death. Since the pandemic started there have been more than 107 million COVID-19 infections caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and ∼2.4 million deaths globally. SARS-CoV-2 is easily transmitted from person-to-person and has spread quickly across all continents. With the continued increase in morbidity and mortality caused by COVID-19, and the damage to the global economy, there is an urgent need for effective prevention and treatment strategies. The advent of safe and effective vaccines has been a significant step forward in the battle against COVID-19, however treatment of the symptoms associated with the disease still requires new anti-viral and anti-inflammatory drug therapies. To this end, scientists have been investigating available natural products that may be effective against SARS-CoV-2, with some products showing promise in fighting several viral infections. Since many natural products are dietary components or are prepared as dietary supplements people tend to consider them safer than synthetic drugs. For example, Traditional Chinese Medicines have been effectively utilized to treat SARS-CoV-2 infected patients with promising results. In this review, we summarize the current knowledge of COVID-19 therapies and the therapeutic potential of medicinal plant extracts and natural compounds for the treatment of several viral infections, with special emphasis on SARS-CoV-2 infection. Realistic strategies that can be employed for the effective use of bioactive compounds for anti-SARS-CoV-2 research are also provided.

4.
Int J Mol Sci ; 22(9)2021 Apr 25.
Article in English | MEDLINE | ID: covidwho-1231493

ABSTRACT

Candida auris is a novel and major fungal pathogen that has triggered several outbreaks in the last decade. The few drugs available to treat fungal diseases, the fact that this yeast has a high rate of multidrug resistance and the occurrence of misleading identifications, and the ability of forming biofilms (naturally more resistant to drugs) has made treatments of C. auris infections highly difficult. This review intends to quickly illustrate the main issues in C. auris identification, available treatments and the associated mechanisms of resistance, and the novel and alternative treatment and drugs (natural and synthetic) that have been recently reported.


Subject(s)
Antifungal Agents/pharmacology , Candida/isolation & purification , Candidiasis/drug therapy , Drug Resistance, Fungal/drug effects , Antifungal Agents/chemistry , Antifungal Agents/therapeutic use , Azoles/pharmacology , Candida/drug effects , Candidiasis/microbiology , Drug Therapy, Combination , Echinocandins/pharmacology , Humans , Mycology/methods , Polyenes/pharmacology , Treatment Failure
5.
Medicina (Kaunas) ; 56(9)2020 Aug 27.
Article in English | MEDLINE | ID: covidwho-738923

ABSTRACT

The positive impact of probiotic strains on human health has become more evident than ever before. Often delivered through food, dietary products, supplements, and drugs, different legislations for safety and efficacy issues have been prepared. Furthermore, regulatory agencies have addressed various approaches toward these products, whether they authorize claims mentioning a disease's diagnosis, prevention, or treatment. Due to the diversity of bacteria and yeast strains, strict approaches have been designed to assess for side effects and post-market surveillance. One of the most essential delivery systems of probiotics is within food, due to the great beneficial health effects of this system compared to pharmaceutical products and also due to the increasing importance of food and nutrition. Modern lifestyle or various diseases lead to an imbalance of the intestinal flora. Nonetheless, as the amount of probiotic use needs accurate calculations, different factors should also be taken into consideration. One of the novelties of this review is the presentation of the beneficial effects of the administration of probiotics as a potential adjuvant therapy in COVID-19. Thus, this paper provides an integrative overview of different aspects of probiotics, from human health care applications to safety, quality, and control.


Subject(s)
Coronavirus Infections/prevention & control , Dietary Supplements/standards , Gastrointestinal Diseases/therapy , Liver Diseases/therapy , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Probiotics/therapeutic use , Betacoronavirus , COVID-19 , Celiac Disease/therapy , Clostridium Infections/therapy , Constipation/therapy , Coronavirus Infections/drug therapy , Coronavirus Infections/therapy , Depressive Disorder/therapy , Diverticular Diseases/therapy , Dysentery/therapy , Enterocolitis, Necrotizing/therapy , Fermented Foods , Food Hypersensitivity/therapy , Helicobacter Infections/therapy , Hepatic Encephalopathy/therapy , Humans , Inflammatory Bowel Diseases/therapy , Non-alcoholic Fatty Liver Disease/therapy , Pneumonia, Viral/therapy , Probiotics/adverse effects , Probiotics/standards , Quality Control , SARS-CoV-2 , COVID-19 Drug Treatment
SELECTION OF CITATIONS
SEARCH DETAIL